Aduro Biotech | Discovering and Developing Immunotherapies.

Immunotherapy

Learn how immunotherapies harness a person’s immune system to fight diseases

STING Pathway

APRIL Pathway

Clinical Trials

Learn more about Aduro’s clinical programs

Investors

Download the 2018 Annual Report

Recent News

August 01, 2019 Aduro Biotech Provides Business Update and Reports Second Quarter 2019 Financial Results

June 02, 2019 Aduro Biotech and Novartis Present Results from Ongoing Phase 1b Study of STING Agonist ADU-S100 (MIW815) in Combination with Anti-PD-1 Monoclonal Antibody Spartalizumab (PDR001) in Patients with Advanced Solid Tumors or Lymphomas

May 15, 2019 Aduro Biotech to Host Investor Event Featuring ADU-S100 (MIW815) Clinical Data Presented at the 2019 American Society of Clinical Oncology Annual Meeting

Careers

Are you interested in working for a company where interactions are authentic, commitment is high and people excel together?